

Mouhab Ayas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5143384/publications.pdf>

Version: 2024-02-01

56
papers

1,051
citations

471509

17
h-index

454955

30
g-index

58
all docs

58
docs citations

58
times ranked

1637
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and risk factors of oral mucositis in paediatric patients undergoing haematopoietic stem cell transplantation. <i>Oral Diseases</i> , 2022, 28, 657-669.	3.0	4
2	HLA-haploidentical donor transplants with post-transplant cyclophosphamide in children with primary immune deficiency disorders. <i>Bone Marrow Transplantation</i> , 2022, 57, 668-670.	2.4	4
3	Hematopoietic Stem Cell Transplantation Stabilizes Cerebral Vasculopathy in High-Risk Pediatric Sickle Cell Disease Patients: Evidence From a Referral Transplant Center. <i>Journal of Hematology (Brossard,)</i> Tj ETQq1 1 0.784314 rgBT /Over	1.0	1
4	Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: Experience from four leading tertiary care hematopoietic stem cell transplantation centers. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 169-178.	0.9	9
5	Experience of treating pediatric hepatoblastoma at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia – Timely surgical intervention playing a key role. <i>International Journal of Pediatrics and Adolescent Medicine</i> , 2021, 8, 39-43.	1.2	1
6	Does Mixed Chimerism After Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients With Fanconi Anemia Impact on Outcome?. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 257.e1-257.e6.	1.2	6
7	Haploidentical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp>. <i>American Journal of Hematology</i> , 2021, 96, 571-579.	4.1	14
8	T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1757-1760.	2.4	5
9	Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. <i>Bone Marrow Transplantation</i> , 2021, 56, 2144-2151.	2.4	16
10	Genetic and clinical characteristics of pediatric patients with familial hemophagocytic lymphohistiocytosis. <i>Blood Research</i> , 2021, 56, 86-101.	1.3	11
11	Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience. <i>International Journal of Pediatrics and Adolescent Medicine</i> , 2021, 8, 253-257.	1.2	1
12	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. <i>Blood Advances</i> , 2021, 5, 262-273.	5.2	9
13	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). <i>Blood</i> , 2021, 138, 2866-2866.	1.4	4
14	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	2.4	7
15	Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.9	0
16	Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1485-1490.	2.4	1
17	Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28340.	1.5	3
18	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30

#	ARTICLE	IF	CITATIONS
19	Travel burden and geographic access to health care among children with cancer in Saudi Arabia. Eastern Mediterranean Health Journal, 2020, 26, 1355-1361.	0.8	0
20	Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2217-2221.	2.0	25
21	Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease. Journal of Clinical Immunology, 2019, 39, 414-420.	3.8	0
22	Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: A population-based analysis. Pediatric Blood and Cancer, 2019, 66, e27684.	1.5	13
23	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018, 24, 799-805.	2.0	22
24	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
25	Prevalence of hereditary cancer susceptibility syndromes in children with cancer in a highly consanguineous population. Cancer Epidemiology, 2018, 55, 88-95.	1.9	13
26	Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra-reduced doses of cyclophosphamide and fludarabine. Pediatric Blood and Cancer, 2018, 65, e27371.	1.5	4
27	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1350-1358.	2.0	25
28	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica, 2017, 102, 1291-1298.	3.5	38
29	Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: A minireview. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 285-289.	0.9	12
30	Hematopoietic stem cell transplantation corrects WIP deficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 1039-1040.e4.	2.9	17
31	Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies. Biotechnology Research International, 2016, 2016, 1-6.	1.4	17
32	Prevalence of hereditary cancer susceptibility syndromes in children: A report from the Saudi Arabian Pediatric Hematology Oncology Society.. Journal of Clinical Oncology, 2016, 34, e13086-e13086.	1.6	0
33	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
34	Hematopoietic stem cell transplant for hyper-IgM syndrome due to CD40L defects: A single-center experience. Pediatric Transplantation, 2015, 19, 634-639.	1.0	10
35	Unrelated Hematopoietic Cell Transplantation in Aplastic Anemia. JAMA Oncology, 2015, 1, 1164.	7.1	1
36	Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, 126, 270-276.	1.4	89

#	ARTICLE	IF	CITATIONS
37	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
38	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1790-1795.	2.0	9
39	Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission. <i>Blood</i> , 2015, 126, 4384-4384.	1.4	0
40	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1868-1875.	3.5	19
41	Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1599-1603.	2.0	28
42	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1238-1243.	2.0	108
43	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 1669-1676.	1.6	69
44	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. <i>Blood</i> , 2013, 122, 4279-4286.	1.4	176
45	Outcome Of Hematopoietic Cell Transplantation (HCT) In Pediatric Patients With Non-Hodgkin Lymphoma (NHL): Single Institution Results From Saudi Arabia. <i>Blood</i> , 2013, 122, 5522-5522.	1.4	0
46	The Saudi Experience in Fludarabine-Based Conditioning Regimens in Patients with Fanconi Anemia Undergoing Stem Cell Transplantation: Excellent Outcome in Recipients of Matched Related Stem Cells but Not in Recipients of Unrelated Cord Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 627-632.	2.0	29
47	Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2011, 4, 121-125.	0.9	5
48	Outcome of second allogeneic stem cell transplantation in pediatric patients with non-malignant hematological and immune deficiency disorders. <i>Pediatric Blood and Cancer</i> , 2011, 56, 289-293.	1.5	3
49	The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults. <i>Blood</i> , 2011, 118, 5237-5237.	1.4	0
50	CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4092-4092.	1.4	0
51	In cyclosporine induced neurotoxicity, is tacrolimus an appropriate substitute or is it out of the frying pan and into the fire?. <i>Pediatric Blood and Cancer</i> , 2008, 50, 426-426.	1.5	10
52	Second Stem Cell Transplantation in Patients with Fanconi Anemia Using Antithymocyte Globulin Alone for Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 445-448.	2.0	14
53	The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. <i>Pediatric Blood and Cancer</i> , 2006, 47, 926-930.	1.5	5
54	Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2001, 113, 938-939.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Metastatic Ewing sarcoma/PNET of bone at diagnosis: Prognostic factors? a report from Saudi Arabia. <i>Medical and Pediatric Oncology</i> , 2001, 37, 383-389.	1.0	16
56	Thiamine-responsive myelodysplasia. <i>British Journal of Haematology</i> , 1998, 102, 1098-1100.	2.5	50